335 related articles for article (PubMed ID: 26177089)
1. A Prospective Cohort Study of Mineral Metabolism After Kidney Transplantation.
Wolf M; Weir MR; Kopyt N; Mannon RB; Von Visger J; Deng H; Yue S; Vincenti F
Transplantation; 2016 Jan; 100(1):184-93. PubMed ID: 26177089
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Use of Cinacalcet in Kidney Transplant Recipients With Hypercalcemic Secondary Hyperparathyroidism: A Single-Center Prospective Study.
Zavvos V; Fyssa L; Papasotiriou M; Papachristou E; Ntrinias T; Savvidaki E; Goumenos DS
Exp Clin Transplant; 2018 Jun; 16(3):287-293. PubMed ID: 29108515
[TBL] [Abstract][Full Text] [Related]
3. The relative role of fibroblast growth factor 23 and parathyroid hormone in predicting future hypophosphatemia and hypercalcemia after living donor kidney transplantation: a 1-year prospective observational study.
Kawarazaki H; Shibagaki Y; Fukumoto S; Kido R; Nakajima I; Fuchinoue S; Fujita T; Fukagawa M; Teraoka S
Nephrol Dial Transplant; 2011 Aug; 26(8):2691-5. PubMed ID: 21303965
[TBL] [Abstract][Full Text] [Related]
4. Natural history of mineral and bone disorders after living-donor kidney transplantation: a one-year prospective observational study.
Kawarazaki H; Shibagaki Y; Fukumoto S; Kido R; Ando K; Nakajima I; Fuchinoue S; Fujita T; Fukagawa M; Teraoka S
Ther Apher Dial; 2011 Oct; 15(5):481-7. PubMed ID: 21974702
[TBL] [Abstract][Full Text] [Related]
5. Post-transplant hypophosphatemia: Tertiary 'Hyper-Phosphatoninism'?
Bhan I; Shah A; Holmes J; Isakova T; Gutierrez O; Burnett SM; Jüppner H; Wolf M
Kidney Int; 2006 Oct; 70(8):1486-94. PubMed ID: 16941023
[TBL] [Abstract][Full Text] [Related]
6. Phosphatemic effect of cinacalcet in kidney transplant recipients with persistent hyperparathyroidism.
Serra AL; Wuhrmann C; Wüthrich RP
Am J Kidney Dis; 2008 Dec; 52(6):1151-7. PubMed ID: 18950915
[TBL] [Abstract][Full Text] [Related]
7. The calcimimetic cinacalcet normalizes serum calcium in renal transplant patients with persistent hyperparathyroidism.
Kruse AE; Eisenberger U; Frey FJ; Mohaupt MG
Nephrol Dial Transplant; 2005 Jul; 20(7):1311-4. PubMed ID: 15941846
[TBL] [Abstract][Full Text] [Related]
8. Hypercalcemia secondary to persistent hyperparathyroidism in kidney transplant patients: analysis after a year with cinacalcet.
Guerra R; Auyanet I; Fernández EJ; Pérez MÁ; Bosch E; Ramírez A; Suria S; Checa MD
J Nephrol; 2011; 24(1):78-82. PubMed ID: 20437396
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and risk factors for tertiary hyperparathyroidism in kidney transplant recipients.
Sutton W; Chen X; Patel P; Karzai S; Prescott JD; Segev DL; McAdams-DeMarco M; Mathur A
Surgery; 2022 Jan; 171(1):69-76. PubMed ID: 34266650
[TBL] [Abstract][Full Text] [Related]
10. Hyperparathyroidism and increased fractional excretion of phosphate predict allograft loss in long-term kidney transplant recipients.
Prakobsuk S; Sirilak S; Vipattawat K; Taweesedt PT; Sumethkul V; Kantachuvesiri S; Disthabanchong S
Clin Exp Nephrol; 2017 Oct; 21(5):926-931. PubMed ID: 27981393
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of hypercalcemia with cinacalcet in renal transplant recipients with persistent hyperparathyroidism.
Serra AL; Schwarz AA; Wick FH; Marti HP; Wüthrich RP
Nephrol Dial Transplant; 2005 Jul; 20(7):1315-9. PubMed ID: 15941845
[TBL] [Abstract][Full Text] [Related]
12. Cinacalcet de novo in persistent hypercalcemia after kidney transplantation secondary to hyperparathyroidism: long-term follow-up and effect of withdrawal.
Paschoalin RP; Torregrosa JV; Barros X; Durán CE; Campistol JM
Transplant Proc; 2012 Oct; 44(8):2376-8. PubMed ID: 23026597
[TBL] [Abstract][Full Text] [Related]
13. Dialysis vintage and parathyroid hormone level, not fibroblast growth factor-23, determines chronic-phase phosphate wasting after renal transplantation.
Tomida K; Hamano T; Ichimaru N; Fujii N; Matsui I; Nonomura N; Tsubakihara Y; Rakugi H; Takahara S; Isaka Y
Bone; 2012 Oct; 51(4):729-36. PubMed ID: 22796419
[TBL] [Abstract][Full Text] [Related]
14. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.
Sprague SM; Wetmore JB; Gurevich K; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1021-30. PubMed ID: 25873267
[TBL] [Abstract][Full Text] [Related]
15. A Randomized Trial of Cinacalcet versus Vitamin D Analogs as Monotherapy in Secondary Hyperparathyroidism (PARADIGM).
Wetmore JB; Gurevich K; Sprague S; Da Roza G; Buerkert J; Reiner M; Goodman W; Cooper K
Clin J Am Soc Nephrol; 2015 Jun; 10(6):1031-40. PubMed ID: 25904755
[TBL] [Abstract][Full Text] [Related]
16. Natural History of Serum Calcium and Parathyroid Hormone Following Renal Transplantation.
Al-Moasseb Z; Aitken E
Transplant Proc; 2016 Dec; 48(10):3285-3291. PubMed ID: 27931570
[TBL] [Abstract][Full Text] [Related]
17. Effective control of persistent hyperparathyroidism with cinacalcet in renal allograft recipients.
Serra AL; Savoca R; Huber AR; Hepp U; Delsignore A; Hersberger M; Wüthrich RP
Nephrol Dial Transplant; 2007 Feb; 22(2):577-83. PubMed ID: 17005527
[TBL] [Abstract][Full Text] [Related]
18. Elevated fibroblast growth factor 23 levels as a cause of early post-renal transplantation hypophosphatemia.
Han SY; Hwang EA; Park SB; Kim HC; Kim HT
Transplant Proc; 2012 Apr; 44(3):657-60. PubMed ID: 22483462
[TBL] [Abstract][Full Text] [Related]
19. Parathyroidectomy in Persistent Post-transplantation Hyperparathyroidism - Single-center Experience.
Meng C; Martins P; Frazão J; Pestana M
Transplant Proc; 2017 May; 49(4):795-798. PubMed ID: 28457397
[TBL] [Abstract][Full Text] [Related]
20. Hypercalcemia in renal transplant patients: prevalence and management in Canadian transplant practice.
Muirhead N; Zaltman JS; Gill JS; Churchill DN; Poulin-Costello M; Mann V; Cole EH
Clin Transplant; 2014 Feb; 28(2):161-5. PubMed ID: 24329899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
